DavidCharlesFajgenbaumMDMBA, MSc

PubMed

• 1 citations
  Letter to the editor regarding 'Non-cirrhotic portal hypertension associated with multicentric Castleman's disease: a case report'.
  Dale Kobrin, Ana Luisa Pinto, Sophia A. T. Parente, Marília Gomes, Maria Augusta Cipriano, Maria Leticia Ribeiro, David C. Fajgenbaum> ;Acta Oncologica. 2019 Feb 15
• 33 citations
  Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial...
  Deanna E Morra, Sheila K Pierson, Dustin Shilling, Sepideh Nemat, Carlos Appiani, Mary Guilfoyle, Craig Tendler, Frits van Rhee, David C. Fajgenbaum> ;British Journal of Haematology. 2019 Jan 1
• 37 citations
  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
  David C. Fajgenbaum> ;Hematology. American Society of Hematology. Education Program. 2018 Nov 30
• 64 citations
  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
  David C. Fajgenbaum> ;Blood. 2018 Nov 29
• 190 citations
  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
  Frits van Rhee, Peter M. Voorhees, Angela Dispenzieri, Alexander Fosså, Gordan Srkalovic, Makoto Ide, Nikhil C. Munshi, Stephen Schey, Matthew Streetly, Sheila K Piers...> ;Blood. 2018 Nov 15
• 13 citations
  A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease.
  Turner S. Baker, Kristyne J. Gambino, Lawrence Schriefer, Jung-Yeon Lim, Karyn Meltz Steinberg, David C. Fajgenbaum, Alejandro Martín García-Sancho, Minji Byun> ;Blood Advances. 2018 Nov 13
• 22 citations
  Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference.
  Jinmin Lee, Victoria P. Werth, Russell P. Hall, R. Eming, Janet A. Fairley, David C. Fajgenbaum, Karen E. Harman, Marcel F. Jonkman, Neil J. Korman, Ralf Ludwig, Dedee...> ;Frontiers in Medicine. 2018 Nov 8
• 6 citations
  Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.
  S. Soudet, David C. Fajgenbaum, Claire Delattre, Alexandra Forestier, Eric Hachulla, Pierre Yves Hatron, David Launay, Louis Terriou> ;Current Research in Translational Medicine. 2018 Sep 1
• 19 citations
  Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease.
  Yu-Jun Dong, Lu Zhang, Lin Nong, Li-Hong Wang, Ze-Yin Liang, Daobin Zhou, David C. Fajgenbaum, Hanyun Ren, Jian Li> ;Annals of Hematology. 2018 May 7
• 53 citations
  Castleman Disease Pathogenesis.
  David C. Fajgenbaum, Dustin Shilling> ;Hematology/oncology Clinics of North America. 2018 Feb 1
• 105 citations
  The full spectrum of Castleman disease: 273 patients studied over 20 years
  Eric Oksenhendler, David Boutboul, David C. Fajgenbaum, Adrien Mirouse, Claire Fieschi, Marion Malphettes, Laetitia Vercellino, Véronique Meignin, Laurence Gérard, Lio...> ;British Journal of Haematology. 2018 Jan 1
• 107 citations
  Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease
  Li Yu, Meifeng Tu, Jorge E. Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva S. Neelapu, Prajwal C. Boddu, Mary Akosile, Thomas S...> ;Blood. 2017 Mar 23
• 297 citations
  International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease
  David C. Fajgenbaum, Thomas S. Uldrick, Adam Bagg, Dale Frank, David Wu, Gordan Srkalovic, David Simpson, Amy Y. Liu, David M. Menke, Shanmuganathan Chandrakasan, Mary...> ;Blood. 2017 Mar 23
• 29 citations
  The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research
  David C. Fajgenbaum, Jason R. Ruth, Dermot Kelleher, Arthur H. Rubenstein> ;The Lancet. Haematology. 2016 Apr 1
• 176 citations
  Idiopathic multicentric Castleman's disease: a systematic literature review
  Amy Y. Liu, Christopher S. Nabel, Brian S. Finkelman, Jason R. Ruth, Razelle Kurzrock, Frits van Rhee, Vera P. Krymskaya, Dermot Kelleher, Arthur H. Rubenstein, David ...> ;The Lancet. Haematology. 2016 Apr 1
• 21 citations
  Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease
  David C. Fajgenbaum, Razelle Kurzrock> ;Immunotherapy. 2016 Jan 1
• 6 citations
  Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research.
  Samantha Kass Newman, Raj Jayanthan, Grant W. Mitchell, Jossie A. Carreras Tartak, Michael P. Croglio, Alexander Suarez, Amy Y. Liu, Beatrice M. Razzo, Enny Oyeniran, ...> ;The Yale Journal of Biology and Medicine. 2015 Nov 24
• A Rare Disease That Picked the Wrong Family: Fighting Back to Help a Loved One and as a Tool for Actively Coping A review of Rare, a documentary video produced and di...
  Fajgenbaum D> ;Death Stud. 2015 Feb 18
• 211 citations
  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.
  David C. Fajgenbaum, Frits van Rhee, Christopher S. Nabel> ;Blood. 2014 May 8
• 35 citations
  Eruptive Cherry Hemangiomatosis Associated With Multicentric Castleman Disease A Case Report and Diagnostic Clue
  David C. Fajgenbaum, Misha Rosenbach, Frits van Rhee, Adnan Nasir, Jason Reutter> ;JAMA Dermatology. 2013 Feb 1
• Join now to see all

Journal Articles

• Cytokine Storm  
  David Fajgenbaum, MD, The New England Journal of Medicine
• Predictors of Response to Anti‐IL6 Monoclonal Antibody Therapy (Siltuximab) in Idiopathic Multicentric Castleman Disease: Secondary Analyses of Phase II Clinical Trial...  
  David C Fajgenbaum, Craig Tendler, British Journal of Haematology
• International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease  
  Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Amy Chadburn, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Th..., Blood
• Predictors of response to anti-IL6 monoclonal antibody therapy(siltuximab) in idiopathic multicentric Castleman disease:secondary analyses of phase II clinical trial data  
  Deanna E. Morra, Sheila K. Pierson, Dustin Shilling, Sepideh Nemat, Carlos Appiani, Mary Guilfoyle, Craig Tendler, Frits van Rhee, David C. Fajgenbaum, British Journal of Haematology, 1/1/2018
• The full spectrum of Castleman Disease: 273 patients studied over 20 years  
  Eric Oksenhendler, David Boutboul, David C. Fajgenbaum, Adrien Mirouse, Claire Fieschi, Marion Malphettes, Laetitia Vercellino, V�ronique Meignin, Laurence G�rard, Lio..., British Journal of Hematology, 1/1/2018
• Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease  
  Sheila K. Pierson, Aaron J. Stonestrom, Dustin Shilling, Jason Ruth, Christopher S. Nabel, Amrit Singh, Yue Ren, Katie Stone, Hongzhe Li, Frits van Rhee, David C. Fajg..., American Journal of Hematology, 1/1/2018
• Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: a case report and clue to pathophysiology  
  Simon Soudet, David C Fajgenbaum, L. Scherman, C. Delattre, A . Forestier, A. Lanteri, E. Hachulla, PY Hatron, David Launay, Louis Terriou, Current Research in Translational Medicine, 1/1/2018
• A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease  
  Turner S. Baker, Kristyne J. Gambino, Lawrence Schriefer, Jung-Yeon Lim, Karyn Meltz Steinberg, David C. Fajgenbaum, Alejandro Mart�n Garc�a-Sancho, Minji Byun, Blood Advances, 1/1/2018
• Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease  
  Yujun Dong, Lu Zhang, Lin Nong, Lihong Wang, Zeyin Liang, Daobin Zhou, David C. Fajgenbaum, Hanyun Ren, Jian Li, Annals of Hematology, 1/1/2018
• Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference  
  Jinmin Lee, Victoria P. Werth, Russell P. Hall, R�diger Eming, Janet A. Fairley, David C. Fajgenbaum, Karen E. Harman, Marcel F. Jonkman, Neil J. Korman, Ralf J. Ludwi..., Front Med, 1/1/2018
• TAFRO Syndrome in Caucasians: A Case Report and Review of the Literature  
  Celine Louis, Sandrine Vijgen, Kaveh Samii, Yves Chalandon, Louis Terriou, David Launay, David C. Fajgenbaum, Jorg D. Seebach, Yannick D. Muller, Frontiers in Medicine, 1/1/2017
• Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome  
  Fatemah Behnia, Saeed Elojeimy, Manuela Matesan, David C. Fajgenbaum, Annals of Hematology, 1/1/2017
• Leveraging information and collaboration to cure disease  
  David C. Fajgenbaum, Information Services & Use, 1/1/2017
• TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease  
  Gordan Srkalovic, Inga Marijanovic, Maya B Srkalovic, David C. Fajgenbaum, Bosn J Basic Med Sci, 1/1/2017
• The future of Castleman disease research: proceedings from 2015 and 2016 annual meetings  
  Michael P. Croglio, Raj K. Jayanthan, Hayley Williamson, Melanie Kier, Amy Y. Liu, Helen L. Partridge, Sheila K. Pierson, Jason R. Ruth, David C. Fajgenbaum, Journal of Rare Disorders, 1/1/2017
• Idiopathic Multicentric Castleman's Disease: A Systematic Literature Review  
  Amy Y. Liu, Christopher S. Nabel, Brian S. Finkelman, Jason R. Ruth, Razelle Kurzrock, Frits van Rhee, Vera P. Krymskaya, Dermot P. Kelleher, Arthur H. Rubenstein, Dav..., The Lancet Haematology, 1/1/2016
• Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease  
  Noriko Iwaki, David C. Fajgenbaum, Christopher S. Nabel, Yuka Gion, Eisei Kondo, Mitsuhiro Kawano, Taro Masunari, Isao Yoshida, Hiroshi Moro, Koji Nikkuni, Kazue Takai..., American Journal of Hematology, 1/1/2016
• The Collaborative Network Approach: A New Framework to Accelerate Castleman Disease and Other Rare Disease Research  
  David C. Fajgenbaum, Jason R. Ruth, Dermot P. Kelleher, Arthur H. Rubenstein, The Lancet Haematology, 1/1/2016
• Rare Disease Research Requires (and benefits from) Global Collaboration: Three Examples from the Castleman Disease Collaborative Network  
  Hayley Williamson, Grant Mitchell, Emily Zhen, Auryn Enciso, Samantha Kass Newman, Deise Ahagon, Mike Croglio, Jason Ruth, Raj Jayanthan, Amy Yutong Liu, Alexander Sua..., Revista de Medicina, 1/1/2016
• Living Life Laser-Focused: A Young Man Forced To Be Both Doctor and Patient  
  Alessia Minicozzi & David C. Fajgenbaum, Journal of Clinical Research & Bioethics, 1/1/2015
• A Rare Disease That Picked the Wrong Family: Fighting Back to Help a Loved One and as a Tool for Actively Coping A review of Rare, a documentary video produced directe...  
  David C. Fajgenbaum, Death Studies, 1/1/2015
• Eruptive Cherry Hemangiomatosis associated with Multicentric Castleman's Disease: A Case Report and possible Mechanism  
  David C. Fajgenbaum, Frits van Rhee, Adnan Nasir, Misha Rosenbach, Jason Reutter, JAMA Dermatology, 1/1/2013
• Building a Network of Grief Support on College Campuses: A National Grassroots Initiative  
  David C. Fajgenbaum, Ben Chesson, Robin Lanzi, The Journal of College Student Psychotherapy, 1/1/2012
• Join now to see all

Books/Book Chapters

• Hematology/Oncology Clinics of North America: Castleman's Disease 
  Chapter: Castleman Disease Pathogenesis 
  David C. Fajgenbaum & Dustin ShillingEditors: Frits van Rhee, Nikhil C. Munshi.Elsevier2018
• Multiple myeloma, the state of the art 
  Chapter: Castleman Disease 
  Page 259 - 270Amy Y Liu & David C. FajgenbaumEditors: Jorge Vega.Permanyer2017
• We Get It: Voices of Grieving College Students and Young Adults 
  Heather Servaty-Seib & David C. FajgenbaumJessica Kingsley Publishers2015
• Georgetown Leadership Book 
  Chapter: Turning ideas into enterprises: Young social entrepreneurship on the Hilltop and beyond 
  David C. Fajgenbaum2007
• Join now to see all

Abstracts/Posters

• Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare
  David C Fajgenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease
  David C Fajgenbaum, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Hypercytokine-Producing Cells and Oligoclonal T-Cell Populations in Lymph Nodes from Castleman Disease Patients
  Anna Wiing, Wenzhao Meng, Gerald Wertheim, Dale Frank, Michele Paessler, Megan S. Lim, Eline T. Luning Prak, David C Fajgenbaum, Vinodh Pillai, Blood (ASH Annual Meeting Abstracts), 1/1/2018
• Pi3k/Akt/Mtor Pathway Activity Is Increased in Lymph Node Tissue from Idiopathic Multicentric Castleman Disease Patients with Tafro Syndrome
  Dustin Shilling, Dale M Kobrin, David C Fajgenbaum, Blood (ASH Annual Meeting Abstracts), 1/1/2018
• Oligoclonal Expansion of Cd8+ T Cells during Idiopathic Multicentric Castleman Disease Flares Suggests an Antigen Driven Process
  Dustin Shilling, Jason E Stadanlick, Wenzhao Meng, Abhishek Rao, Vera P Krymskaya, Eline T. Luning Prak, Evgeniy B Eruslanov, David C Fajgenbaum, Blood (ASH Annual Meeting Abstracts), 1/1/2018
• Serum Proteomics Reveals Distinct Subtypes Associated with Treatment Response in Idiopathic Multicentric Castleman Disease
  Dustin Shilling, Jason R Ruth, Christopher Sheild Nabel, Sheila K Pierson, Mary Guilfoyle, Craig Tendler, Manjula P Reddy, Michael Weinblatt, Nancy Shadick, Mark Bower..., Blood (ASH Annual Meeting Abstracts), 1/1/2018
• Single-Cell RNA-Sequencing of Peripheral Blood Mononuclear Cells Reveals Changes in Immune Cell Composition and Distinct Inflammatory Gene Expression Profiles during I...
  Ruth-Anne Langan, Dustin Shilling, Michael Gonzalez, Charlly Kao, HakonHakonarson, Taku Kambayashi, David C Fajgenbaum, Blood (ASH Annual Meeting Abstracts), 1/1/2018
• Virome Capture Sequencing in Castleman disease identifies associations with herpesviridae family members but no novel viruses
  Christopher S. Nabel, Stephen Sameroff, Dustin Shilling, Jason Ruth, Mitsuhiro Kawano, Yasuharu Sato, Noriko Iwaki, Federico Valdivieso, Michael Feldman, Katie Stone, ..., Blood (ASH Annual Meeting Abstracts), 1/1/2017
• Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach
  David C. Fajgenbaum, Dustin Shilling, Helen L. Partridge,Sheila Pierson, Jason R. Ruth, Christopher S. Nabel, Vandana Chaturvedi, Michael B. Jordan, MD5, Adam D. Cohen..., Blood (ASH Annual Meeting Abstracts), 1/1/2017
• Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease
  David C. Fajgenbaum, Sheila K. Pierson, Dustin Shilling, Cooper Gardner, Amy Y. Liu, Jasira Ziglar, Shawnee Bernstein, Sarah Mann, Jeremy Zuckerberg, Martin Lukac, Raj..., Blood (ASH Annual Meeting Abstracts), 1/1/2017
• Quantification of Plasma Proteins from Idiopathic Multicentric Castleman Disease Flares and Remissions Reveals 'Chemokine Storm' and Separates Clinical Subtypes
  Sheila Pierson, Aaron James Stonestrom, Jason R Ruth, Dustin Shilling, Hongzhe Li, Yue Ren, Katie Stone, Frits van Rhee, David C. Fajgenbaum, Blood (ASH Annual Meeting Abstracts), 1/1/2017
• Join now to see all

Lectures

• Frontiers in Medicine: Personalized Medicine 
  1/1/2019
• Overtime: Battling a deadly disease as a physician, researcher, patient, and entrepreneur 
  1/1/2019
• MOD1 Genetics Case Presentations 
  1/1/2019
• Anxiety-Provoking Consults: Macrophage Activation Syndrome, Castleman Disease, and Hypereosinophilia 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Using an old transplant drug to hit novel targets in the cytokine storm disorder, idiopathic multicentric Castleman disease 
  University of Pennsylvania, Philadelphia, PA - 1/1/2018
• Personalized, Personalized Medicine: Research, Collaboration, and Remission 
  University of Pennsylvania, Philadelphia, PA - 1/1/2018
• Personalized, Personalized Medicine 
  Multiple locations, 2017, 2018 - 1/1/2018
• Personalized, Personalized Medicine: Advancing Science and Survivorship for Castleman Disease 
  Tarrytown, NY - 1/1/2018
• A "Personalized Approach" to Treating Castleman disease 
  Milan, Italy - 1/1/2018
• Accelerating research and therapy for Castleman disease 
  Palo Alto, CA - 1/1/2018
• The Collaborative Network Approach: Accelerating research and treatment discovery for Castleman disease through international collaboration and patient engagement 
  Dana Farber Cancer Institute, Boston, MA - 1/1/2018
• The Collaborative Network Approach: Accelerating research and treatment discovery through international collaboration and patient engagement 
  Orlando, FL - 1/1/2018
• Personalized, personalized medicine in idiopathic multicentric Castleman disease 
  Dana Farber Cancer Institute, Boston, MA - 1/1/2018
• ACCELERATE: Towards Personalized Medicine for Castleman Disease 
  Hopital St. Louis, Paris, France - 1/1/2018
• Personalized, Personalized Medicine for Rare Diseases 
  New York, NY - 1/1/2018
• Fighting for My Life: Orphan Diseases and the Quest for Cures 
  Austin, TX - 1/1/2018
• Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease 
  San Diego, CA - 1/1/2018
• Personalized, Personalized Medicine: Using 'omics' Research and Team Science to Advance Understanding of idiopathic multicentric Castleman disease 
  1/1/2017
• What Should Patients Expect when Funding Basic Research for Rare Diseases: A Patient Advocate's Story 
  1/1/2017
• Overtime 
  Las Vegas, NV, 2017; Boston, MA, 2017 - 1/1/2017
• Targeted treatment for HHV-8-negative, idiopathic multicentric Castleman disease 
  Silver Spring, MD - 1/1/2017
• Personalized, Personalized Medicine: Using 'omics' and Team Science to Advance Understanding of Idiopathic multicentric Castleman disease 
  Grand Rounds, Philadelphia, PA - 1/1/2017
• Overtime: Fighting to cure diseases when every second counts 
  Charlotte, NC - 1/1/2017
• Personalized, Personalized Medicine: Leveraging 'omic' data and team science to uncover a novel therapeutic target for iMCD 
  1/1/2017
• Treating my own disease 
  New York, NY - 1/1/2017
• Join now to see all

Other

• Unicentric Castleman disease 
  David C. Fajgenbaum, UpToDate
  1/1/2018
• HHV-8-associated multicentric Castleman disease 
  David C. Fajgenbaum, UpToDate
  1/1/2018
• HHV-8-negative/idiopathic multicentric Castleman disease 
  David C. Fajgenbaum, UpToDate
  1/1/2018
• Chip Chambers: For rare disease patients a pathway to hundreds of new therapies 
  Max Bronstein, Emil Kakkis, David C. Fajgenbaum, Health Affairs Blog
  1/1/2017
• Castleman Disease 
  David C. Fajgenbaum, NORD
  https://rarediseases.org/rare-diseases/castlemans-disease/
  1/1/2017
• Ask the Hematologists: What are your treatment approaches to Castleman disease with the advent of anti-interleukin-6 therapy? 
  Frits van Rhee & David C. Fajgenbaum, The Hematologist: ASH News and Reports
  1/1/2015
• Death and Loss in the Future as it Relates to Young Adults and National Students of AMF 
  David C. Fajgenbaum & Lisa Fajgenbaum, The ADEC Forum
  1/1/2013
• National Students of AMF: Peer Support and Service as Therapeutic Supports Among Grieving College Students 
  David C. Fajgenbaum, The ADEC Forum
  1/1/2012
• Join now to see all